Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:EXEL
- CUSIP: 30161Q10
- Web: www.exelixis.com
Capitalization:- Market Cap: $7.90898 billion
- Outstanding Shares: 293,904,000
Average Prices:- 50 Day Moving Avg: $26.35
- 200 Day Moving Avg: $22.49
- 52 Week Range: $10.04 - $28.45
P/E:- Trailing P/E Ratio: 135.25
- Foreward P/E Ratio: 46.17
- P/E Growth: 2.24
Sales & Book Value:- Annual Revenue: $319.67 million
- Price / Sales: 24.62
- Book Value: $0.51 per share
- Price / Book: 52.51
Profitability:- EBIDTA: $95.32 million
- Net Margins: 18.20%
- Return on Equity: 80.43%
- Return on Assets: 13.93%
Debt:- Current Ratio: 4.12%
- Quick Ratio: 4.06%
Misc:- Average Volume: 4.23 million shs.
- Beta: 1.89
- Short Ratio: 3.04
Frequently Asked Questions for Exelixis (NASDAQ:EXEL)
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Wednesday, August, 2nd. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.02. The firm earned $99.01 million during the quarter, compared to analysts' expectations of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. Exelixis's revenue for the quarter was up 173.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.15) EPS. View Exelixis' Earnings History.
When will Exelixis make its next earnings announcement?
Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?
11 brokers have issued 12-month price objectives for Exelixis' shares. Their forecasts range from $15.00 to $33.00. On average, they expect Exelixis' stock price to reach $25.08 in the next year. View Analyst Ratings for Exelixis.
What are analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
- 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now. Operating expenses are also projected to increase." (7/11/2017)
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Kite Pharma (KITE), BIOVERATIV INC (BIVV), TESARO (TSRO), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Juno Therapeutics (JUNO), AveXis (AVXS), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Axovant Sciences (AXON), Sarepta Therapeutics (SRPT) and Prothena Corporation PLC (PRTA).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
- Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
- Christopher J. Senner, Chief Financial Officer, Executive Vice President
- Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
- Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
- Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
- Patrick Haley, Senior Vice President - Commercial
- Charles M. Cohen Ph.D., Independent Director
- Carl B. Feldbaum Esq., Independent Director
- Alan M. Garber M.D. Ph.D., Independent Director
Who owns Exelixis stock?
Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.89%), Vanguard Group Inc. (8.66%), Meditor Group Ltd (6.92%), BlackRock Inc. (5.16%), Matrix Capital Management Company LP (5.14%) and Goldman Sachs Group Inc. (2.40%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Who sold Exelixis stock? Who is selling Exelixis stock?
Exelixis' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Farallon Capital Management LLC, Northern Trust Corp, Teachers Advisors LLC, State Street Corp, Acadian Asset Management LLC, Voya Investment Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Who bought Exelixis stock? Who is buying Exelixis stock?
Exelixis' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Matrix Capital Management Company LP, Janus Henderson Group PLC, Meditor Group Ltd, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Exelixis.
How do I buy Exelixis stock?
Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of Exelixis stock can currently be purchased for approximately $26.78.
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.55) |
| Consensus Price Target: | $25.08 (6.34% downside) |
Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/10/2017 | Cowen and Company | Reiterated Rating | Outperform | | Medium |  |
| 8/3/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $29.00 | Low | |
| 8/3/2017 | Deutsche Bank AG | Downgrade | Buy -> Hold | $26.00 -> $29.00 | Medium | |
| 8/3/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $26.00 | High | |
| 7/27/2017 | William Blair | Reiterated Rating | Outperform | | Medium | |
| 7/20/2017 | Cann | Reiterated Rating | Hold | | Low | |
| 7/13/2017 | SunTrust Banks, Inc. | Initiated Coverage | Buy -> Buy | $33.00 | Medium | |
| 6/12/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Hold | | Low | |
| 3/31/2017 | Needham & Company LLC | Initiated Coverage | Buy -> Buy | $28.00 | Medium | |
| 3/16/2017 | CIBC | Initiated Coverage | Market Perform -> Market Perform | | High | |
| 10/7/2016 | Leerink Swann | Reiterated Rating | Positive | $15.00 | N/A | |
| 9/28/2016 | S&P Equity Research | Boost Price Target | | $13.41 -> $15.57 | N/A | |
(Data available from 8/17/2015 forward)
Earnings History for Exelixis (NASDAQ:EXEL)Earnings History by Quarter for Exelixis (NASDAQ EXEL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | $0.05 | | | | | N/A | |
| 8/2/2017 | Q2 2017 | $0.04 | $0.06 | $85.27 million | $99.01 million | View | Listen | |
| 5/1/2017 | Q1 2017 | ($0.01) | $0.05 | $65.23 million | $80.90 million | View | Listen | |
| 2/27/2017 | Q416 | ($0.01) | $0.12 | $64.88 million | $77.58 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.13) | ($0.04) | $43.15 million | $62.19 million | View | N/A | |
| 8/3/2016 | Q216 | ($0.27) | ($0.16) | $16.76 million | $36.25 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.25) | ($0.27) | $9.11 million | $15.40 million | View | Listen | |
| 2/29/2016 | Q415 | ($0.22) | ($0.19) | $8.16 million | $9.94 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.20) | ($0.22) | $9.08 million | $9.85 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.21) | ($0.22) | $8.69 million | $8.00 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.24) | ($0.18) | $8.08 million | $9.40 million | View | Listen | |
| 2/24/2015 | Q414 | ($0.31) | ($0.30) | $7.50 million | $7.35 million | View | Listen | |
| 11/4/2014 | Q314 | ($0.37) | ($0.32) | $6.77 million | $6.30 million | View | Listen | |
| 7/31/2014 | Q214 | ($0.39) | ($0.38) | $5.66 million | $6.56 million | View | Listen | |
| 5/1/2014 | Q114 | ($0.37) | ($0.39) | $6.11 million | $4.90 million | View | Listen | |
| 2/20/2014 | Q413 | ($0.38) | ($0.38) | $5.71 million | $4.34 million | View | Listen | |
| 10/30/2013 | Q313 | ($0.37) | ($0.36) | $5.55 million | $5.50 million | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.30) | ($0.34) | $6.55 million | $11.90 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.29) | ($0.24) | $5.33 million | $9.70 million | View | Listen | |
| 2/21/2013 | Q4 2012 | ($0.24) | ($0.28) | $9.46 million | $7.80 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.30) | ($0.20) | $9.22 million | $13.30 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.25) | | | View | N/A | |
| 5/3/2012 | | ($0.19) | ($0.18) | | | View | N/A | |
| 10/27/2011 | | $0.57 | $0.60 | | | View | N/A | |
| 8/4/2011 | | ($0.17) | ($0.16) | | | View | N/A | |
| 5/3/2011 | | ($0.19) | ($0.24) | | | View | N/A | |
| 2/22/2011 | | ($0.21) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Exelixis (NASDAQ:EXEL)2017 EPS Consensus Estimate: $0.12
2018 EPS Consensus Estimate: $0.54
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.03) | $0.01 | ($0.01) |
| Q2 2017 | 4 | $0.01 | $0.03 | $0.02 |
| Q3 2017 | 4 | $0.05 | $0.07 | $0.06 |
| Q4 2017 | 4 | $0.04 | $0.07 | $0.06 |
| Q1 2018 | 1 | $0.09 | $0.09 | $0.09 |
| Q2 2018 | 1 | $0.10 | $0.10 | $0.10 |
| Q3 2018 | 1 | $0.15 | $0.15 | $0.15 |
| Q4 2018 | 1 | $0.20 | $0.20 | $0.20 |
(Data provided by Zacks Investment Research)
Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 79.93%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/30/2017 | Patrick J. Haley | Insider | Sell | 5,000 | $18.46 | $92,300.00 | |
| 5/15/2017 | Carl B Feldbaum | Director | Sell | 32,988 | $21.58 | $711,881.04 | |
| 5/10/2017 | Michael Morrissey | Insider | Sell | 211,300 | $21.87 | $4,621,131.00 | |
| 5/9/2017 | Michael Morrissey | CEO | Sell | 100,000 | $21.69 | $2,169,000.00 | |
| 5/8/2017 | Michael Morrissey | CEO | Sell | 11,300 | $21.81 | $246,453.00 | |
| 5/5/2017 | Michael Morrissey | Insider | Sell | 259,149 | $22.24 | $5,763,473.76 | |
| 5/1/2017 | Gisela Schwab | CMO | Sell | 89,910 | $23.01 | $2,068,829.10 | |
| 4/3/2017 | Vincent T Marchesi | Director | Sell | 10,000 | $21.30 | $213,000.00 | |
| 3/31/2017 | Jack L Wyszomierski | Director | Sell | 5,150 | $21.57 | $111,085.50 | |
| 3/27/2017 | Jeffrey Hessekiel | EVP | Sell | 6,884 | $21.02 | $144,701.68 | |
| 3/22/2017 | Jeffrey Hessekiel | EVP | Sell | 23,787 | $20.54 | $488,584.98 | |
| 3/20/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $21.66 | $216,600.00 | |
| 3/13/2017 | Charles Cohen | Director | Sell | 10,000 | $21.82 | $218,200.00 | |
| 3/10/2017 | Vincent T Marchesi | Director | Sell | 40,000 | $21.98 | $879,200.00 | |
| 3/6/2017 | Michael Morrissey | Insider | Sell | 200,000 | $22.72 | $4,544,000.00 | |
| 3/3/2017 | Christopher J. Senner | CFO | Sell | 11,000 | $22.80 | $250,800.00 | |
| 3/2/2017 | George Poste | Director | Sell | 76,250 | $22.53 | $1,717,912.50 | |
| 1/3/2017 | Peter Lamb | EVP | Sell | 70,000 | $14.65 | $1,025,500.00 | |
| 12/16/2016 | Carl B. Feldbaum | Director | Sell | 25,000 | $17.03 | $425,750.00 | |
| 12/9/2016 | Alan M. Garber | Director | Sell | 7,832 | $16.90 | $132,360.80 | |
| 12/7/2016 | George A. Scangos | Director | Sell | 204,894 | $17.81 | $3,649,162.14 | |
| 12/5/2016 | George A. Scangos | Director | Sell | 204,718 | $17.81 | $3,646,027.58 | |
| 12/1/2016 | Gisela Schwab | Insider | Sell | 22,000 | $16.73 | $368,060.00 | |
| 12/1/2016 | Peter Lamb | EVP | Sell | 70,000 | $16.66 | $1,166,200.00 | |
| 8/4/2016 | Gisela Schwab | Insider | Sell | 42,338 | $11.00 | $465,718.00 | |
| 5/11/2016 | Lance Willsey | Director | Buy | 60,000 | $4.97 | $298,200.00 | |
| 5/9/2016 | Lance Willsey | Director | Buy | 40,000 | $4.97 | $198,800.00 | |
| 12/11/2015 | Lance Willsey | Director | Buy | 100,000 | $4.89 | $489,000.00 | |
| 10/16/2015 | Peter Lamb | EVP | Sell | 51,549 | $5.80 | $298,984.20 | |
| 10/13/2015 | Peter Lamb | EVP | Sell | 600 | $5.80 | $3,480.00 | |
| 10/12/2015 | Peter Lamb | EVP | Sell | 300,276 | $5.84 | $1,753,611.84 | |
| 9/17/2014 | Vincent T Marchesi | Director | Buy | 20,000 | $1.71 | $34,200.00 | |
| 8/29/2013 | Lance Willsey | Director | Buy | 10,000 | $5.15 | $51,500.00 | |
| 12/20/2012 | Vincent T Marchesi | Director | Buy | 4,000 | $4.68 | $18,720.00 | |
| 12/19/2012 | Vincent T Marchesi | Director | Buy | 6,000 | $4.72 | $28,320.00 | |
| 12/10/2012 | Gisela Schwab | EVP | Buy | 25,000 | $4.39 | $109,750.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
| Source: |
|
| Date | Headline |
|---|
 | Exelixis (EXEL) Submits sNDA for CABOMETYX for Treatment of Previously Untreated Advanced Kidney Cancer
www.streetinsider.com - August 16 at 11:39 PM |
 | Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer
finance.yahoo.com - August 16 at 6:38 PM |
| Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc.
finance.yahoo.com - August 16 at 6:38 PM |
| See what the IHS Markit Score report has to say about Exelixis Inc.
finance.yahoo.com - August 14 at 11:57 PM |
| IHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 11 at 7:00 PM |
 | Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts - Motley Fool
www.fool.com - August 9 at 11:44 PM |
| Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts
www.fool.com - August 9 at 11:19 AM |
 | Leerink Swann Equities Analysts Cut Earnings Estimates for Exelixis, Inc. (NASDAQ:EXEL)
www.americanbankingnews.com - August 7 at 9:56 AM |
| Exelixis, Inc. Forecasted to Post Q1 2018 Earnings of $0.09 Per Share (NASDAQ:EXEL)
www.americanbankingnews.com - August 7 at 7:58 AM |
| SunTrust Banks Brokers Increase Earnings Estimates for Exelixis, Inc. (EXEL)
www.americanbankingnews.com - August 7 at 7:46 AM |
| Exelixis, Inc. Expected to Earn Q3 2017 Earnings of $0.07 Per Share (EXEL)
www.americanbankingnews.com - August 7 at 7:08 AM |
 | Exelixis Earnings: Did The Market Respond Appropriately? - Seeking Alpha
seekingalpha.com - August 4 at 11:48 PM |
| Exelixis, Inc. Grows Revenue, Eyes Treating More Patients - Motley Fool
www.fool.com - August 4 at 11:48 PM |
| Oppenheimer Holdings Analysts Increase Earnings Estimates for Exelixis, Inc. (NASDAQ:EXEL)
www.americanbankingnews.com - August 4 at 6:02 PM |
| Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
www.fool.com - August 4 at 3:10 PM |
| Exelixis, Inc. Forecasted to Earn Q3 2017 Earnings of $0.06 Per Share (EXEL)
www.americanbankingnews.com - August 4 at 8:02 AM |
| Q3 2017 EPS Estimates for Exelixis, Inc. (EXEL) Boosted by William Blair
www.americanbankingnews.com - August 4 at 8:02 AM |
| Exelixis, Inc. to Post Q3 2017 Earnings of $0.05 Per Share, SunTrust Banks Forecasts (NASDAQ:EXEL)
www.americanbankingnews.com - August 4 at 8:02 AM |
 | The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom - Benzinga
www.benzinga.com - August 4 at 1:28 AM |
 | Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales ... - Nasdaq
www.nasdaq.com - August 4 at 1:28 AM |
| The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom
finance.yahoo.com - August 3 at 8:27 PM |
| Exelixis, Inc. (EXEL) Releases Earnings Results
www.americanbankingnews.com - August 3 at 6:24 PM |
| 3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
www.fool.com - August 3 at 4:12 PM |
 | Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales
www.zacks.com - August 3 at 3:26 PM |
| Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch
finance.yahoo.com - August 3 at 3:26 PM |
| Exelixis, Inc. (EXEL) Rating Lowered to Hold at Deutsche Bank AG
www.americanbankingnews.com - August 3 at 8:56 AM |
 | Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update - Business Wire (press release)
www.businesswire.com - August 3 at 5:27 AM |
| Edited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT
finance.yahoo.com - August 3 at 5:27 AM |
| Exelixis (EXEL) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 12:25 AM |
| Exelixis tops Street 2Q forecasts
finance.yahoo.com - August 3 at 12:25 AM |
| Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 2 at 7:24 PM |
| Exelixis beats by $0.02, beats on revenue
seekingalpha.com - August 2 at 4:15 PM |
| Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress
finance.yahoo.com - August 2 at 12:12 AM |
| Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress - Business Wire (press release)
www.businesswire.com - August 1 at 7:09 PM |
| Exelixis, Inc. (NASDAQ:EXEL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 1 at 8:58 AM |
| Zacks: Brokerages Anticipate Exelixis, Inc. (NASDAQ:EXEL) Will Announce Quarterly Sales of $84.58 Million
www.americanbankingnews.com - August 1 at 8:05 AM |
| Commit To Buy Exelixis At $17, Earn 11.5% Using Options - Nasdaq
www.nasdaq.com - July 31 at 6:14 PM |
| ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up
finance.yahoo.com - July 31 at 6:14 PM |
| Zacks: Brokerages Expect Exelixis, Inc. (EXEL) Will Announce Earnings of $0.03 Per Share
www.americanbankingnews.com - July 30 at 6:25 PM |
| Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up
finance.yahoo.com - July 28 at 5:05 AM |
| Exelixis, Inc. (NASDAQ:EXEL) Rating Reiterated by William Blair
www.americanbankingnews.com - July 27 at 5:14 PM |
 | Opinion: Three biotech companies to watch ahead of earnings - MarketWatch
www.marketwatch.com - July 25 at 6:44 PM |
 | Technical Snapshots for These Biotech Stocks -- Exelixis, Celldex Therapeutics, Clovis Oncology, and Geron
www.bizjournals.com - July 24 at 8:00 PM |
| What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
www.zacks.com - July 24 at 8:00 PM |
| What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
finance.yahoo.com - July 24 at 7:59 PM |
| FY2019 Earnings Estimate for Exelixis, Inc. (NASDAQ:EXEL) Issued By Leerink Swann
www.americanbankingnews.com - July 24 at 11:30 AM |
| FY2018 EPS Estimates for Exelixis, Inc. Raised by Leerink Swann (NASDAQ:EXEL)
www.americanbankingnews.com - July 21 at 3:32 PM |
| FY2018 EPS Estimates for Exelixis, Inc. Lowered by William Blair (EXEL)
www.americanbankingnews.com - July 21 at 3:30 PM |
| William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)
finance.yahoo.com - July 21 at 3:17 PM |
| 2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
finance.yahoo.com - July 21 at 3:17 PM |
Exelixis (EXEL) Chart for Thursday, August, 17, 2017
